The growing demand for controlled immunological research and therapeutic development has spurred significant improvements in recombinant growth factor manufacture. IL-1A, IL-1B, IL-2, and IL-3, each possessing unique physiological roles, are frequently produced using multiple expression platforms, including prokaryotic hosts, mammalian cell culture